Illustration: Gabriella Turrisi/Axios
THL Partners is acquiring a majority stake in pharma services company Celerion from H.I.G. for $1.8 billion, Axios Pro has learned.
Why it matters: Private equity interest in pharma services persists, as biotech funding rebounds and more complex drugs come to market.
